Bosutinib
Spezifikationen
380843-75-4CAS-Nummer
700-455-1EG-Nummer
4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrileIUPAC-Name
C26H29Cl2N5O3Chemische Formel
530.4 g/molMolekulargewicht
Bosutinib; 380843-75-4; SKI-606; SKI 606; 4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile; 4-((2,4-dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile; 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile; SK-606; 4-((2,4-dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methyl-1-piperazinyl)propoxy)-3-quinolinecarbonitrile; 5018V4AEZ0; CHEBI:39112; DTXSID10861568; 3-Quinolinecarbonitrile, 4-((2,4-dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methyl-1-piperazinyl)propoxy)-; bosutinibum; uglysycpd2; RefChem:58901; DTXCID40207910; L01XE14; 4-Anilinobenzo(g)quinoline-3-carbonitrile; 700-455-1; 943-866-3; 4-Anilino-3-quinolinecarbonitrile; Bosutinib (SKI-606); BOSULIF; SKI606; 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile; Bosutinib (USAN); Bosutinib [USAN]; MFCD07367846; 4-(2,4-dichloro-5-methoxyphenylamino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile; BOSUTINIB ISOMER 1; CHEMBL288441; C26H29Cl2N5O3; SKI-606); 4-(2,4-dichloro-5-methoxy-anilino)-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile; Bosutinib [USAN:INN]; NCGC00241107-01; UNII-5018V4AEZ0; Bosutinib API; Bosutinib (Standard); Bosutinib,SKI-606; BOSUTINIB [INN]; BOSUTINIB [MI]; BOSUTINIB [VANDF]; PF-5208763; BOSUTINIB [MART.]; EC 700-455-1; BOSUTINIB [WHO-DD]; Bosutinib (SKI-606)?; MLS006011212; SCHEMBL158390; BDBM4552; GTPL5710; orb1225150; orb1310890; orb3141310; Bosutinib Isomer 1, Free Base; Bosutinib, >=98% (HPLC); SCHEMBL29350234; SCHEMBL29428159; EX-A391; UBPYILGKFZZVDX-UHFFFAOYSA-N; GLXC-90178; HMS2043A22; HMS3244A03; HMS3244A04; HMS3244B03; HMS3651C03; HMS3672K11; HMS3743E09; HMS5079M03; K00615a; EBC-11336; HB1323; HY-10158R; NSC765694; NSC799367; SK 606; AKOS015902521; AC-2413; CCG-208129; CS-0118; DB06616; FB19002; NSC-765694; NSC-799367; PB30881; SDCCGSBI-0646926.P001; NCGC00241107-03; NCGC00241107-05; NCGC00241107-06; AS-11064; HY-10158; SMR002530350; NS00002757; S1014; SW220197-1; D03252; AB01565836_03; EN300-7565041; F794031; Q894611; SR-01000941572; SR-01000941572-1; BRD-K99964838-001-01-0; BRD-K99964838-001-06-9; BRD-K99964838-001-11-9; BRD-K99964838-001-12-7; Z2216885221; 3-QUINOLINECARBONITRILE, 4-((2,4-DICHLORO-5-METHOXYPHENYL)AMINO)-6-METHYL-1-PIPERAZINYL)PROPOXY)-; 4-(2,4-Dichloro-5-methoxy-phenylamino)-6-methoxy-7-[3-(4-methyl-piperazin-1-yl)propoxy]quinoline-3-carbonitrileSynonyme
Produkte, die Bosutinib enthalten
BOSUTINIB ZENTIVA 500 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFGBOSUTINIB ZENTIVA 400 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFGBOSUTINIB ZENTIVA 100 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFGBOSUTINIB STADA 500 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFGBOSUTINIB STADA 400 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFGBOSUTINIB STADA 100 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFGBOSUTINIB DR. REDDYS 500 COMPRIMIDOS RECUBIERTOS CON PELICULA EFGBOSUTINIB DR. REDDYS 400 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFGBOSUTINIB DR. REDDYS 100 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFGBOSUTINIB ZENTIVA 500 mg, comprimé pelliculéBOSUTINIB ZENTIVA 400 mg, comprimé pelliculéBOSUTINIB ZENTIVA 100 mg, comprimé pelliculé
Seite 1 von 3
Unternehmen, die Bosutinib verkaufen
ML
MSN LaboratoriesIndiaRP
Reddy Pharma Iberia S.A.SpainLC
LEAP CHEM CO., LTD.Seite 1 von 2